Citable filing context
MDT's research view summarizes recent SEC filing context, starting with divestiture from Sep 17, 2026.
| Filed | Item | Context |
|---|---|---|
| Sep 17, 2026 | divestiture | Medtronic commenced an exchange offer of up to 225,361,295 MiniMed Group shares for Medtronic ordinary shares. |
| Sep 1, 2026 | earnings | Medtronic reported Q1 fiscal 2027 revenue of $9.8 billion and raised its full-year organic revenue growth guidance. |
| Jun 3, 2026 | earnings | Medtronic reported Q4 revenue of $9.8 billion and full year 2026 revenue of $36.4 billion. |
| Sep 1, 2026 | Guidance: non_gaap_diluted_eps | 5.94 to 6.00 |
| Sep 1, 2026 | Guidance: organic_revenue_growth | 7.25 to 7.75 |
| Jun 3, 2026 | Guidance: diluted_non_gaap_eps | 5.90 to 6.00 |
| Sep 3, 2026 | mda_quarterly | Medtronic generated net sales of $9.76 billion for the three months ended July 31, 2026, a 14% year-over-year increase supported by approximately $570 million from an extra calendar week. GAAP diluted EPS increased to $1.14, while non-GAAP EPS reached $1.45. Operating cash flow rose to $1.79 billion, delivering free cash flow of $1.29 billion. Revenue growth spanned all major portfolios. Cardiovascular sales increased 20% to $3.93 billion, led by a 30% surge in Electrophysiology Therapies driven by pulsed field ablation platforms—including PulseSelect and Affera—alongside steady demand for CoreValve Evolut TAVR systems. Neuroscience revenue grew 10% to $2.68 billion, pushed by the AiBLE spine ecosystem and Percept neurostimulators. Medical Surgical gained 10% to $2.28 billion, buoyed by expanding global adoption of the Hugo robotic-assisted surgery system and LigaSure technology. Diabetes revenue grew 17% to $843 million on MiniMed 780G adoption ahead of its anticipated full separation this fiscal year. Inorganic growth was highlighted by the strategic acquisitions of Scientia Vascular for $681 million and SPR Therapeutics for $654 million. Key operating risks include Chinese volume-based procurement tenders, global trade tariff policies, and integration and transaction expenses tied to corporate separations. |
| Jun 18, 2026 | business | Medtronic plc is a leading global healthcare technology company operating across three primary segments: Cardiovascular, Neuroscience, and Medical Surgical. A major strategic milestone is the separation of its Diabetes business (MiniMed Group, Inc.), which completed its IPO in March 2026. Within Cardiovascular, key product lines include the Micra leadless pacemaker, Evolut TAVR systems, Symplicity Spyral renal denervation for hypertension, and Affera pulsed field ablation catheters. The Neuroscience segment is anchored by the AiBLE spine technology ecosystem, Mazor robotic guidance, and Inceptiv closed-loop spinal cord stimulators. Medical Surgical highlights include the Hugo robotic-assisted surgery system and the GI Genius AI-powered endoscopy module. Products are sold globally through direct sales representatives and independent distributors. Medtronic faces intense competition, including from pharmaceutical alternatives like GLP-1s, alongside pricing pressures driven by hospital consolidation, group purchasing organizations, and volume-based procurement tenders in China. Key operational risks include a highly stringent and evolving global regulatory environment—specifically compliance with the EU Medical Device Regulation (MDR) and emerging AI frameworks—ongoing intellectual property litigation, and potential supply chain disruptions due to reliance on sole-source suppliers for critical raw materials and components. |
Source: SEC EDGAR filing text and events; period Sep 17, 2026; filed Sep 17, 2026.
MDT company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.